This is very positive. If it doesn't pop the share price it doesn't matter because this is a strong orphan drug contender (H2 2024) with a good likelihood, in my opinion, of being out-licensed in the US.
NRX Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt
CC9 Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings
Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back
SER How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign
